Greene Calls on DOJ to Probe Covid Vaccine Safety After Child Death Report

Rep. Marjorie Taylor Greene says the Justice Department should launch an immediate investigation into Covid vaccine safety, following reports that a child died during a Moderna clinical trial.

By yourNEWS Media Newsroom

Outgoing Rep. Marjorie Taylor Greene (R-Ga.) on Wednesday demanded that the Department of Justice open an investigation into what she called “deadly Covid jabs,” responding to new reporting on a child’s death allegedly linked to a vaccine trial.

“There should be a DOJ investigation immediately and Covid vaccines should lose their FDA approval,” Greene wrote in a post on X. “There has been no accountability for all the vaccine injuries and deaths. It’s beyond maddening.”

Her statement followed journalist Alex Berenson’s report that a preschool-aged child died of cardiac arrest after receiving a booster shot during Moderna’s Covid vaccine clinical trials. Berenson published his findings on Substack, alleging that Moderna failed to publicly disclose the death in its trial registry or related publications.

“Moderna has not reported the death to a public trial registry or published results that show the death, effectively hiding it for years,” Berenson wrote. “What did the FDA know and did it respond? The agency won’t say.”

Greene’s remarks come days after she renewed calls for the prosecution of former National Institute of Allergy and Infectious Diseases Director Anthony Fauci, who was pardoned in January 2025 by Joe Biden. President Donald Trump has since declared that all autopen-signed pardons issued under Biden’s administration are null and void.

In an earlier post, Greene accused Fauci of being “instrumental” in promoting the mRNA vaccine rollout and in advancing government-funded gain-of-function research.

It is unclear whether the Trump administration or the DOJ will formally respond to Greene’s request for an investigation. The issue of vaccine accountability has reemerged as a flashpoint in post-pandemic policy debates, with advocates pressing for transparency on clinical trial data and government oversight of pharmaceutical safety practices.